“Pre-Filled Device Manufacturing market set to grow to $8.3bn by 2024” says new Visiongain report

02 September 2019
Pharma

Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2019-2029: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services.

Pre-filled syringes provide users with a number of advantages over other drug delivery systems. These include simplified storage and disposal, shorter preparation and administration time and reduced risk of medication errors. For drug manufacturers, there are also numerous advantages to pre-filled syringes. Filling syringes rather than vials cuts overfill rates, reducing wastage, and also eliminates material costs as there is no need for vials as well as syringes.

The lead analyst of the report commented "Most companies have invested in new manufacturing facilities or sales offices in emerging markets, to take advantage of lower cost manufacturing, as well as in order to appeal to emerging market drug developers. A particular target group among these companies are biosimilar developers looking to bring their drugs to developed markets. Companies have also invested in products suitable for administration of these biosimilars, as well as novel biologics. These include dual-chamber syringes and cartridges, lyophilisation and reconstitution tools, sensitive syringe coatings and polymer syringes."

Leading companies featured in the report include Aptar Stelmi, Becton, Dickinson, & Co (BD), Bespak Injectables, Boehringer Ingelheim, Catalent, Dätwyler Holding, Gerresheimer, Haselmeier, Laboratorios Farmacéuticos ROVI and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever